The partnership combines ViewsML’s virtual IHC platform with iProcess customers, enabling faster, tissue-sparing biomarker testing
ViewsML, an AI-powered virtual immunohistochemistry (IHC) staining company, and iProcess Global Research, a provider of biospecimen and clinical research solutions, are partnering with ViewsML to broaden access to its virtual biomarker technology
iProcess will offer ViewsML virtual IHC technology to its network of research institutions, diagnostic labs and pharmaceutical partners. The partnership means customers can now access digital pathology tools that eliminate the need for physical biomarker staining, accelerating turnaround times, preserving rare tissue samples, and enabling multiplex analysis in silico.
Keith Jalbert, chief commercial officer at VeiwsML, said: “We’re excited to partner with iProcess to bring the benefits of our virtual IHC platform to their customers.”
“iProcess has an exceptional reputation for biospecimen access, histopathology services, and operational scale. By integrating our AI-powered virtual staining into their offerings, researchers and drug developers will be able to generate high-resolution, quantitative biomarker insights in seconds—not days—whilst increasing the value of every tissue sample.”
ViewsML's platform helps researchers in predicting biomarker expression at the per-cell level, using only a single H&E image, fitting into existing pathology workflows. The company's virtual panels support a vast range of biomarkers with applications in research to diagnostics.
For iProcess, the collaboration will enhance its digital pathology capabilities, unlocking new service offerings for pharmaceutical clients and academic partners seeking to maximise sample utility, accelerating biomarker-driven decisions.
Asker Ahmed, director and founder at iProcess, said: “We see ViewsML’s virtual IHC as a game-changer for the way tissue samples are characterised and utilised.”
“Our clients are demanding faster, more scalable, and cost-effective biomarker analysis—especially in early drug discovery and high-throughput settings. With ViewsML as a partner, we can now offer AI-powered tissue interrogation with unmatched speed, precision, and tissue preservation. We’re thrilled to bring this innovation to our clients.”
